PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-12.98%
Negative revenue growth while CRON.TO stands at 6.47%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-5.67%
Negative gross profit growth while CRON.TO is at 27.08%. Joel Greenblatt would examine cost competitiveness or demand decline.
-77.54%
Negative EBIT growth while CRON.TO is at 69.05%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-77.54%
Negative operating income growth while CRON.TO is at 64.17%. Joel Greenblatt would press for urgent turnaround measures.
-23.37%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-11.75%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-11.75%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
10.30%
Slight or no buybacks while CRON.TO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
10.30%
Slight or no buyback while CRON.TO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
-213.44%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-293.67%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
-49.02%
Negative 5Y CAGR while CRON.TO stands at 336.01%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-38.88%
Negative 3Y CAGR while CRON.TO stands at 57.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-73.69%
Negative 10Y OCF/share CAGR while CRON.TO stands at 66.51%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
63.22%
5Y OCF/share CAGR at 50-75% of CRON.TO's 93.86%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
80.56%
3Y OCF/share CAGR at 75-90% of CRON.TO's 92.43%. Bill Ackman would press for improvements in margin or overhead to catch up.
-1805.63%
Negative 10Y net income/share CAGR while CRON.TO is at 216.45%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-176.55%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
51.73%
Below 50% of CRON.TO's 122.97%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
9259.09%
10Y equity/share CAGR above 1.5x CRON.TO's 1707.62%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
-35.28%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-58.67%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.30%
AR growth is negative/stable vs. CRON.TO's 6.67%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
4.84%
Inventory growth well above CRON.TO's 4.39%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-1.69%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-8.28%
We have a declining book value while CRON.TO shows 25.27%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
0.29%
We have some new debt while CRON.TO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
-73.35%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-19.29%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.